Bavarian Nordic A/S 2013 SR
The report highlights Bavarian Nordic's transition to a fully integrated vaccine company, achieving its first product approvals in the EU and Canada in 2013. The company successfully reduced its aggregate CO2 emissions by 9% and improved production efficiencies, maintaining a relative climate impact below index 100 per dose produced. Key focus areas included employee health and safety, with a noted decrease in sickness absence despite an increase in minor occupational accidents. The company also prepared for the global Phase 3 study of its prostate cancer immunotherapy, PROSTVAC, and expanded its production facilities in Denmark.
Company: Bavarian Nordic A/S
Sector: Manufacturing
Country: Denmark
Year: 2013
Type: SR
Pages: 26
Back to company
Bavarian Nordic A/S
CSR Report
The report highlights Bavarian Nordic's transition to a fully integrated vaccine company, achieving its first product approvals in the EU and Canada in 2013. The company successfully reduced its aggregate CO2 emissions by 9% and improved production efficiencies, maintaining a relative climate impact below index 100 per dose produced. Key focus areas included employee health and safety, with a noted decrease in sickness absence despite an increase in minor occupational accidents. The company also prepared for the global Phase 3 study of its prostate cancer immunotherapy, PROSTVAC, and expanded its production facilities in Denmark.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2013
Reporting Period
Jan 1, 2013 - Dec 31, 2013
Fiscal Year
2013
Published
Mar 19, 2014
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
Other Standards
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Total Waste
Women on Board
Women in Management
Employees